ទំព័រដើម › ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ › នូវកាឡូណាខាងជើង › Durham
ការសាកល្បងគ្លីនិកសម្រាប់ ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ នៅក្នុង Durham, NC
ការសិក្សាចំនួន 33 សម្រាប់ ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ Durham (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Durham VA Medical Center, Durham
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Duke University Medical Center, Durham
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Duke University Medical Center, Durham
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Duke University Medical Center, Durham
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Duke University Medical Center, Durham
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
កំពុងជ្រើសរើសដំណាក់កាល 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Duke University Medical Center, Durham
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
កំពុងជ្រើសរើសដំណាក់កាល 1
- University of North Carolina at Chapel Hill, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- UNC School of Medicine, Division of Hematology, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
កំពុងជ្រើសរើសដំណាក់កាល 3
- US-Chapel Hill-UNCNORTHCAROLINA, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
កំពុងជ្រើសរើសដំណាក់កាល 1
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
កំពុងជ្រើសរើសដំណាក់កាល 3
- Duke University Medical Center, Durham
- University of North Carolina, Chapel Hill, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1
- University of North Carolina at Chapel Hill, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Research Site, Durham
- Research Site, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
កំពុងជ្រើសរើសដំណាក់កាល 2
- University of North Carolina at Chapel Hill, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
កំពុងជ្រើសរើស
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
Registry of Older Patients With Cancer
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
កំពុងជ្រើសរើសដំណាក់កាល 2
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
A Study of Revumenib and Mezigdomide in People With Leukemia
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- University of North Carolina (Data Collection Only), Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
កំពុងជ្រើសរើសដំណាក់កាល 1
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
កំពុងជ្រើសរើសដំណាក់កាល 1
- University of North Carolina, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Duke University, Durham
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
កំពុងជ្រើសរើសដំណាក់កាល 2
- University of North Carolina, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
កំពុងជ្រើសរើសដំណាក់កាល 1
- Duke Blood Cancer Center, Durham
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
កំពុងជ្រើសរើសដំណាក់កាល 1
- Duke Cancer Center, Durham
Novel Digital Application for Patients With Acute Leukemia
កំពុងជ្រើសរើស
- Duke University, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Duke University Medical Center, Durham
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
កំពុងជ្រើសរើសស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Duke University, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · ឆ្ងាយ 10 ម៉ាយ
ការសាកល្បងសម្រាប់ ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ នៅក្នុងទីក្រុងផ្សេងទៀត
- Houston, TXការសិក្សា 85
- New York City, NYការសិក្សា 51
- Boston, MAការសិក្សា 44
- Seattle, WAការសិក្សា 41
- Baldwin Park, CAការសិក្សា 40
- Columbus, OHការសិក្សា 35
- Philadelphia, PAការសិក្សា 34
- Atlanta, GAការសិក្សា 31
- Tampa, FLការសិក្សា 29
- Chicago, ILការសិក្សា 26
- Portland, ORការសិក្សា 25
- Washington, DCការសិក្សា 24
ការសិក្សាផ្សេងទៀតនៅក្នុង Durham
- មហារីកទ្រូងការសិក្សា 64
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 58
- Non-Small Cell Lung Cancerការសិក្សា 39
- ជំងឺ Multiple Myelomaការសិក្សា 37
- មហារីកដែលរីករាលដាលការសិក្សា 33
- មហារីកតូចការសិក្សា 32
- មហារីកសួតការសិក្សា 32
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 28
- មហារីកស៊ុតការសិក្សា 27
- ជំងឺលីម្វូស៊ីតប្រចាំការសិក្សា 27
- បេះដូងខ្សោយការសិក្សា 26
- មហារីកតំបក់ការសិក្សា 24
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 6 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។